tetano
Editor, Senior Moderator
Nat Med
. 2020 Sep 15.
doi: 10.1038/s41591-020-1088-9. Online ahead of print.
Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study
Sean T H Liu[SUP] 1 2 [/SUP], Hung-Mo Lin[SUP] 3 [/SUP], Ian Baine[SUP] 4 [/SUP], Ania Wajnberg[SUP] 5 [/SUP], Jeffrey P Gumprecht[SUP] 1 [/SUP], Farah Rahman[SUP] 1 [/SUP], Denise Rodriguez[SUP] 6 [/SUP], Pranai Tandon[SUP] 7 [/SUP], Adel Bassily-Marcus[SUP] 8 [/SUP], Jeffrey Bander[SUP] 9 [/SUP], Charles Sanky[SUP] 10 [/SUP], Amy Dupper[SUP] 1 [/SUP], Allen Zheng[SUP] 2 [/SUP], Freddy T Nguyen[SUP] 4 [/SUP], Fatima Amanat[SUP] 2 11 [/SUP], Daniel Stadlbauer[SUP] 2 [/SUP], Deena R Altman[SUP] 1 [/SUP], Benjamin K Chen[SUP] 1 [/SUP], Florian Krammer[SUP] 2 [/SUP], Damodara Rao Mendu[SUP] 4 [/SUP], Adolfo Firpo-Betancourt[SUP] 4 [/SUP], Matthew A Levin[SUP] 12 [/SUP], Emilia Bagiella[SUP] 3 [/SUP], Arturo Casadevall[SUP] 13 [/SUP], Carlos Cordon-Cardo[SUP] 4 [/SUP], Jeffrey S Jhang[SUP] 4 [/SUP], Suzanne A Arinsburg[SUP] 4 [/SUP], David L Reich[SUP] 12 [/SUP], Judith A Aberg[SUP] 1 [/SUP], Nicole M Bouvier[SUP] 14 15 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a new human disease with few effective treatments[SUP]1[/SUP]. Convalescent plasma, donated by persons who have recovered from COVID-19, is the acellular component of blood that contains antibodies, including those that specifically recognize SARS-CoV-2. These antibodies, when transfused into patients infected with SARS-CoV-2, are thought to exert an antiviral effect, suppressing virus replication before patients have mounted their own humoral immune responses[SUP]2,3[/SUP]. Virus-specific antibodies from recovered persons are often the first available therapy for an emerging infectious disease, a stopgap treatment while new antivirals and vaccines are being developed[SUP]1,2[/SUP]. This retrospective, propensity score-matched case-control study assessed the effectiveness of convalescent plasma therapy in 39 patients with severe or life-threatening COVID-19 at The Mount Sinai Hospital in New York City. Oxygen requirements on day 14 after transfusion worsened in 17.9% of plasma recipients versus 28.2% of propensity score-matched controls who were hospitalized with COVID-19 (adjusted odds ratio (OR), 0.86; 95% confidence interval (CI), 0.75-0.98; chi-square test P value = 0.025). Survival also improved in plasma recipients (adjusted hazard ratio (HR), 0.34; 95% CI, 0.13-0.89; chi-square test P = 0.027). Convalescent plasma is potentially effective against COVID-19, but adequately powered, randomized controlled trials are needed.
. 2020 Sep 15.
doi: 10.1038/s41591-020-1088-9. Online ahead of print.
Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study
Sean T H Liu[SUP] 1 2 [/SUP], Hung-Mo Lin[SUP] 3 [/SUP], Ian Baine[SUP] 4 [/SUP], Ania Wajnberg[SUP] 5 [/SUP], Jeffrey P Gumprecht[SUP] 1 [/SUP], Farah Rahman[SUP] 1 [/SUP], Denise Rodriguez[SUP] 6 [/SUP], Pranai Tandon[SUP] 7 [/SUP], Adel Bassily-Marcus[SUP] 8 [/SUP], Jeffrey Bander[SUP] 9 [/SUP], Charles Sanky[SUP] 10 [/SUP], Amy Dupper[SUP] 1 [/SUP], Allen Zheng[SUP] 2 [/SUP], Freddy T Nguyen[SUP] 4 [/SUP], Fatima Amanat[SUP] 2 11 [/SUP], Daniel Stadlbauer[SUP] 2 [/SUP], Deena R Altman[SUP] 1 [/SUP], Benjamin K Chen[SUP] 1 [/SUP], Florian Krammer[SUP] 2 [/SUP], Damodara Rao Mendu[SUP] 4 [/SUP], Adolfo Firpo-Betancourt[SUP] 4 [/SUP], Matthew A Levin[SUP] 12 [/SUP], Emilia Bagiella[SUP] 3 [/SUP], Arturo Casadevall[SUP] 13 [/SUP], Carlos Cordon-Cardo[SUP] 4 [/SUP], Jeffrey S Jhang[SUP] 4 [/SUP], Suzanne A Arinsburg[SUP] 4 [/SUP], David L Reich[SUP] 12 [/SUP], Judith A Aberg[SUP] 1 [/SUP], Nicole M Bouvier[SUP] 14 15 [/SUP]
Affiliations
- PMID: 32934372
- DOI: 10.1038/s41591-020-1088-9
Abstract
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a new human disease with few effective treatments[SUP]1[/SUP]. Convalescent plasma, donated by persons who have recovered from COVID-19, is the acellular component of blood that contains antibodies, including those that specifically recognize SARS-CoV-2. These antibodies, when transfused into patients infected with SARS-CoV-2, are thought to exert an antiviral effect, suppressing virus replication before patients have mounted their own humoral immune responses[SUP]2,3[/SUP]. Virus-specific antibodies from recovered persons are often the first available therapy for an emerging infectious disease, a stopgap treatment while new antivirals and vaccines are being developed[SUP]1,2[/SUP]. This retrospective, propensity score-matched case-control study assessed the effectiveness of convalescent plasma therapy in 39 patients with severe or life-threatening COVID-19 at The Mount Sinai Hospital in New York City. Oxygen requirements on day 14 after transfusion worsened in 17.9% of plasma recipients versus 28.2% of propensity score-matched controls who were hospitalized with COVID-19 (adjusted odds ratio (OR), 0.86; 95% confidence interval (CI), 0.75-0.98; chi-square test P value = 0.025). Survival also improved in plasma recipients (adjusted hazard ratio (HR), 0.34; 95% CI, 0.13-0.89; chi-square test P = 0.027). Convalescent plasma is potentially effective against COVID-19, but adequately powered, randomized controlled trials are needed.